Compare Direxion Daily S&P 500 Bull 3X Shares (SPXL) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion Daily S&P 500 Bull 3X Shares vs Spyre Therapeutics Inc. Common Stock — how do they compare? Direxion Daily S&P 500 Bull 3X Shares trades at $283.85 (market cap $7.36B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Direxion Daily S&P 500 Bull 3X Shares and Spyre Therapeutics Inc. Common Stock are close in size by market cap, and Direxion Daily S&P 500 Bull 3X Shares is trading nearer its 52-week high, Spyre Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Direxion Daily S&P 500 Bull 3X Shares for 33 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| SPXL | SYRE | |
|---|---|---|
Market Cap | $7.36B | $7.52B |
Volume | 1,127,892 | 1,441,031 |
Sector | Leveraged / Inverse | Health |
52-Week High | $301.38 | $108.92 |
52-Week Low | $170.20 | $22.18 |
Typical Hold Time | 33 Days | 0 Days |
Enterprise Value | — | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPXL trades at $297.37 with no daily change, maintaining a bullish technical stance supported by moving averages. The ETF shows neutral oscillator signals with RSI at 75.74 suggesting potential overbought conditions. Recent news highlights S&P 500 valuation concerns amid strong profit growth expectations of 35% for 2026, though projections slow to 15% for 2027 according to Wall Street analysts.
The ETF's outlook remains tied to S&P 500 performance, with seasonal patterns and earnings growth as key catalysts. Risks include market concentration in top holdings and geopolitical uncertainty. Analyst sentiment is mixed with technical indicators favoring upside while fundamental valuations warrant caution given projected earnings deceleration.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Direxion Daily S&P 500 Bull 3X Shares
SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
